Browsing Tag
Food and Drug Administration
25 posts
NB.1.8.1 variant monitored by WHO as global spread accelerates in May 2025
NB.1.8.1 spreads across U.S., India, and China in May 2025; WHO designates as Variant Under Monitoring. No rise in severity reported yet.
COVID-19 still killing 300 Americans weekly in 2025: Low vaccine uptake blamed
More than 300 Americans still die from COVID weekly. Find out why vaccine uptake, variant risks, and treatment gaps keep the toll high in 2025.
Co-Diagnostics revamps COVID-19 test for FDA clearance amid stability concerns
Co-Diagnostics, Inc. has announced that it is withdrawing its 510(k) clearance application for its Co-Dx PCR COVID-19 test…
Shocking mix-up in tortilla strips puts millions with wheat allergies at risk
Sugar Foods Corporation has announced a recall of its Fresh Gourmet Tortilla Strips Santa Fe Style, citing concerns…
FDA shocks Neurotech with rejection of orphan drug status for life-changing PANDAS/PANS treatment
Neurotech International Limited is facing an uphill battle after the United States Food and Drug Administration (FDA) declined…
LifeVantage stock soars on game-changing GLP-1 study results – here’s what you need to know
Shares of LifeVantage Corporation have jumped 8.2% after the company announced encouraging results from a study on its…
This new FDA-approved insulin pump just sent Modular Medical’s stock soaring 27%—Find out why!
Shares of Modular Medical, Inc. soared by 27% to reach $2.49, surpassing its previous 52-week high of $2.22,…
FDA approves Janssen’s TECVAYLI for multiple myeloma treatment
The Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, announced the US Food and Drug Administration’s approval…
Ayala Pharmaceuticals AL102 gets FDA fast track status in desmoid tumors
Ayala Pharmaceuticals has been granted fast track designation for its oral gamma-secretase inhibitor AL102 by the US Food…
Lupin launches generic Suprep Bowel Prep Kit in the US after FDA approval
Lupin launches FDA-approved generic Suprep Bowel Prep Kit in the US, entering a $202M market and expanding its gastrointestinal portfolio.